KRAS-activating mutations occur in about 25% of NSCLC [5,6,7] and are associated with the development of a primary resistance to TKIs [8], therefore limiting the long-term clinical benefits of this kind of therapy in KRAS-mutated NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.